Osnat Fabian-Ashur
Tel Aviv, TA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
DIO3 associates with sorting nexins and endosomal trafficking networks in ovarian cancer.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: March 03, 2026
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer.
Journal: Molecular oncology
Published: August 27, 2023
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
Journal: Cancer letters
Published: April 27, 2023
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Journal: Oncogene
Published: March 16, 2023
Editorial: Crosstalk between thyroid hormones, analogs and ligands of integrin αvβ3 in health and disease. Who is talking now?
Journal: Frontiers in endocrinology
Published: December 09, 2022
Three-Dimensional Modeling of Thyroid Hormone Metabolites Binding to the Cancer-Relevant αvβ3 Integrin: In-Silico Based Study.
Journal: Frontiers in endocrinology
Published: March 13, 2022
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality.
Journal: Endocrine-related cancer
Published: August 04, 2021
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Journal: Oncogene
Published: June 01, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
Journal: Autophagy
Published: February 26, 2021
αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia.
Journal: Journal of clinical medicine
Published: February 25, 2021
Last Updated: 09/26/2026